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Recently, tumor microenvironment (TME) and its 
stromal constituents have provided profound insights 
into understanding alterations in tumor behavior. After 
each identification regarding the unique roles of TME 
compartments, non-malignant stromal cells are found to 
provide a sufficient tumorigenic niche for cancer cells. Of 
these TME constituents, adipocytes represent a dynamic 
population mediating endocrine effects to facilitate the 
crosstalk between cancer cells and distant organs, as well as 
the interplay with nearby tumor cells. To date, the prevalence 
of obesity has emphasized the significance of metabolic 
homeostasis along with adipose tissue (AT) inflammation, 
cancer incidence, and multiple pathological disorders. In this 
review, we summarized distinct characteristics of hypertrophic 
adipocytes and cancer to highlight the importance of an 
individual's metabolic health during cancer therapy. As 
AT undergoes inflammatory alterations inducing tissue 
remodeling, immune cell infiltration, and vascularization, 
these features directly influence the TME by favoring tumor 
progression. A comparison between inflammatory AT and 
progressing cancer could potentially provide crucial insights 
into delineating the complex communication network 
between uncontrolled hyperplastic tumors and their 
microenvironmental components. In turn, the comparison 
will unravel the underlying properties of dynamic tumor 
behavior, advocating possible therapeutic targets within TME 
constituents.
Keywords: adipose tissue, cancer-associated adipocyte, 
inflammation, obesity, tumor microenvironment
INTRODUCTION
To date, heterogeneous features of tumor cells have empha-
sized the challenges to comprehensively treat cancer. More-
over, a lethal characteristic of cancer to develop multidrug 
resistance has contributed to the continuous modification of 
current treatment strategies in cancers (Tolios et al., 2020). 
Thus, therapeutic targeting has shifted from tumor cell-intrin-
sic pathways to the bidirectional communication between the 
tumor and its microenvironmental compartments (Hanahan 
and Coussens, 2012; Hanna et al., 2009; Roma-Rodrigues 
et al., 2019). Investigating these interactions has manifested 
extensive hallmarks for changes in tumor behavior; however, 
identifying substantial crosstalk between various cell types 
within TME remains complex (Hui and Chen, 2015).
 The prevalence of obesity worldwide has tripled since 
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1975, increasing the incidence of chronic inflammation, 
insulin resistance, type 2 diabetes mellitus (T2DM), and car-
diovascular diseases (CVD). Adipose tissue (AT) inflammation 
and metabolic dysfunction are proposed to influence tumor-
igenesis and cancer progression (Lengyel et al., 2018). This 
interaction between AT and cancer has been well document-
ed, with severe effects observed among adipocyte-rich can-
cers such as breast, colon, prostate, ovarian, and pancreatic 
cancers (Table 1). Thus, the profound influence of systemic 
inflammation on the whole body emphasizes the importance 
of an individual’s metabolic health during cancer treatment. 
 A small number of approaches have attempted to list the 
commonalities between growing tumors and inflammatory 
AT. However, numerous factors such as cytokines, extra-
cellular matrix (ECM), immune cells, hypoxic factors, and 
fibroblasts affect tumor growth and AT expansion in similar 
manners. During proliferation, similar arrays of cytokines, 
such as transforming growth factor-β (TGF-β), tumor necrosis 
factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-
1), and other pro-inflammatory cytokines, are secreted from 
both tumor cells and adipocytes to their surroundings, repro-
gramming the ECM to favor growth (Fig. 1) (Berraondo et 
al., 2019). The reconstruction of the TME and AT is a compa-
rable phenomenon since both conditions pursue adipogenic 
and tumorigenic niche via vascularization during expansion 
(Hinrichs and Rosenberg, 2014; Romagnani et al., 2001). 
Therefore, the classification of environmental changes in the 
AT provides profound insights into unraveling the mechanism 
underlying the dynamic tumor behavior, especially when the 
tumor is adjacent to a large population of adipocytes. Fur-
thermore, this comparison may suggest effective therapeutic 
targets for TME, which could alleviate inflammatory stress 
from both tumorigenic regions and AT.
OVERVIEW OF ADIPOSE TISSUE INFLAMMATION
AT is mainly composed of adipocytes that play a pivotal role 
as energy storage. Additionally, AT senses the nutrient status 
to regulate energy mobilization depending on its nutritional 
accessibility (Zhang et al., 2003). As a crucial endocrine or-
gan, AT relies on adipocytes that secrete hormones through 
coordinating with other adjacent and distant tissues (Reilly 
Fig. 1. Inflammatory AT and TME synergistically communicate to favor the growth of cancer cells. Commonalities between propagating 
adipocytes and cancer cells reshaping ECM constituents and stiffness are illustrated above. The interplay between adipocytes and TME 
integrates multiple factors. Fibroblasts from both inflammatory AT and TME induce fibrosis which reorganizes ECM compartments. 
IL-6 secreted from cancer cells causes adipocyte dedifferentiation and delipidation to supply FFA to tumor cells. MCP-1 and CXCL12 
cooperatively mediate macrophage infiltration into both AT and TME, where M1 and M2 polarization can be alternatively converted 
depending on the environmental conditions. Vascularization fulfills oxygen and nutritional demands for both adipocytes and cancer cells.
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and Saltiel, 2017). However, under conditions of overnutri-
tion, AT expansion occurs due to hypertrophic adipocytes. 
During nutritional excess, the enlarged adipocytes cause AT 
dysfunction, augmenting systemic inflammation that is highly 
implicated in insulin resistance and T2DM (Fischer-Posovszky 
et al., 2011). Numerous physiological outcomes are manifest-
ed during AT inflammation; for example, increased lipolysis 
resulting in hydrolysis of triglyceride (TG) to three free fatty 
acids (FFAs) and glycerol. In turn, the metabolic health of an 
individual is severely impaired, and numerous adipokines are 
altered.
 Fibrosis, a phenomenon of dysfunctional AT, is character-
ized by excessive deposition of ECM. Here, myofibroblasts 
produce ECM components, namely collagen, fibronectin, 
and glycoproteins. TGF-β, platelet-derived growth factor-α 
(PDGF-α), and HIF1-α represent the activators of profibrotic 
myofibroblast differentiation (Buechler et al., 2015; Marcelin 
et al., 2019). Excessive deposition of ECM enhances its ri-
gidity, resulting in angiogenic properties of AT. For instance, 
desmoplasia occurs with a process of disrupted tissue ho-
meostasis during inflammation regulation mediated by myo-
fibroblasts, which deposit stiff matrix components, including 
fibrillar collagens and fibronec tins (Quail and Dannenberg, 
2019). Moreover, TGF-β and PDGF-α control ECM dynamics 
by regulating metalloproteinases (MMPs) and tissue inhibitor 
of matrix metalloproteinase-1 (TIMP-1) to mediate ECM re-
construction (Sun et al., 2013). Adjustment of ECM stiffness, 
rigidity, and composition is an essential procedure to accom-
modate hypertrophic adipocytes (Seo et al., 2015).
 AT components, such as fibroblasts, preadipocytes, tis-
sue-resident macrophages, and vascular constituents termed 
adipose tissue macrophages (ATMs), contribute to prop-
agating pro-inflammatory responses under hypertrophic 
conditions (Huh et al., 2014; Ikeoka et al., 2010). ATMs 
represent the most abundant class of leukocytes, originating 
from blood monocytes (Russo and Lumeng, 2018). These 
macrophages are arranged around dead adipocytes, form-
ing crown-like structures (CLS), which are hallmarks of the 
pro-inflammatory process in AT. Though the macrophage 
polarization status M1 (pro-inflammatory) and M2 (anti-in-
flammatory) could be an over-simplification, macrophages in 
inflammatory AT generally exhibit more M1 polarized pheno-
types (Huh et al., 2014; Nguyen et al., 2007; Patsouris et al., 
2008; Quail and Dannenberg, 2019).
 The secretory pro-inflammatory response in AT involves 
TNF-α, IL-6, MCP-1, inducible nitric oxide synthase (iNOS), 
TGF-β, and HIF1-α (Greenberg and Obin, 2006; Hotamisligil 
et al., 1993). Indeed, macrophages infiltrating into AT and 
cancer are both responsible for local TNF-α and IL-6 secretion 
(Weisberg et al., 2003). This secretion mediates direct com-
munication between adipocytes and nearby compartments, 
followed by induction of angiogenic factors. For instance, 
HIF1-α, expressed from adipocytes during AT inflammation, 
directly regulates the transcription of vascular endothelial 
growth factor (VEGF) (He et al., 2011). Reduced adiponectin 
secretion during obesity promotes TNF-α-induced monocyte 
adhesion and vascularization (Palanisamy et al., 2019). Con-
versely, leptin induces angiogenesis, vascular fenestration, 
and vascular remodeling (Buechler et al., 2015).
AN OVERVIEW OF THE TUMOR MICROENVIRONMENT
TME comprises a variety of cellular (fibroblasts, endothelial 
cells, pericytes, and adipocytes) and non-cellular (growth fac-
tors, cytokines, RNA, DNA, metabolites, and ECM) compo-
nents exchanging a substantial network of signals. The vast 
networks of communication within the TME compartments 
include proliferative signals, resistance to apoptosis, uncon-
trolled multiplication, vascularization, and immune evasion 
(Petrova et al., 2018). Often followed by hypoxic conditions, 
the ECM of malignant cancers undergo dynamic alterations 
in its components, which are critical determinants of tumor 
behavior and differentiation (Walker et al., 2018).
 The ECM comprises a complex mixture of macromolecules 
with major components providing structural support. Fibro-
blasts maintain the ECM homeostasis via collagen synthesis, 
which is implicated in the structural deposition that under-
goes constant reconstruction during tumor progression (Eble 
and Niland, 2019; Fang et al., 2014). Fibroblasts are stromal 
tissue that forms a baseline for membrane compartments, 
regulate differentiation of epithelial cells, modulate immune 
responses, and mediate tissue homeostasis (Kalluri and Zeis-
berg, 2006; Quail and Joyce, 2013). Fibroblasts adjacent to 
malignant tumor cells are activated by growth factors, cell-cell 
communication, and reactive oxygen species (ROS), acquiring 
abnormal features to transform into cancer-associated fibro-
blasts (CAFs). Particularly, during tumor progression, TGF-β, 
fibroblast growth factor (FGF), and PDGF stimulate the tran-
sition from normal fibroblasts to CAFs. CAFs then produce 
MMPs, modulating Notch and p53 signaling pathways, re-
leasing angiogenic factors, reprograming ECM plasticity and 
architecture (Bauer et al., 2010; Quail and Joyce, 2013; Xing 
et al., 2010).
 Fibrillar collagen is one of the dominant components of 
ECM. Growing evidence has indicated that collagen under-
goes qualitative and quantitative reorganization to provide a 
supportive structure for tumor progression (Sun et al., 2013; 
Zhou et al., 2017). Collagens directly interact with cancer 
cells through the discoidin domain receptor (DDR) to mediate 
the behavioral changes during cancer. Furthermore, cancer 
cells also reshape collagen to reinforce the cell-collagen loop, 
which gradually fosters cancer progression. Additionally, the 
direct binding of integrin and collagen leads to the activation 
of the Akt/PI3K, MAPK, Rho, and MEK/ERK signaling path-
ways, thereby inducing cell proliferation and evasion of apop-
tosis (Xu et al., 2019a).
 The proliferating tumor inevitably develops a hypoxic envi-
ronment that drives signal transduction via the upregulation 
of HIFs within the microenvironment. In the tumor, the most 
compelling consequence of excessive oxygen and nutrient 
demand is the secretion of angiogenic and lymphangiogenic 
factors (Ji, 2014). The correlation between the HIF pathway 
and pro-angiogenic genes to promote vascular permeabil-
ity, endothelial cell proliferation, migration, adhesion, and 
tube formation is well elicited (Bos et al., 2005; Bryant et al., 
2010). Additionally, hypoxia is involved in the regulation of 
multiple transcription factors, including Notch and Wnt sig-
naling, to induce multiple gene expressions associated with 
EMT, cell cycle progression, and survival (Jung et al., 2015). 
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Thus, hypoxia exerts a powerful impact on the surrounding 
hyperplastic tumor cells.
 Based on epidemiological studies, the link between obesity 
and cancer progression has been proposed. In addition to 
the role of WAT to store energy, it also acts as an endocrine 
organ, secreting an extensive variety of adipokines commu-
nicating with both proximal and distant organs (Paz et al., 
2011). Though overnutrition is accompanied by multiple 
systemic effects, the co-culture system suggests the direct ef-
fects of adipokines and FFA on tumor behavior. Interestingly, 
it has been reported that dysfunctional AT determines tumor 
malignancy, entailing massive contributions of adipocytes 
toward cancer progression and metastasis (Johnson et al., 
2012).
INVESTIGATING THE INTERRELATIONSHIP BETWEEN 
ADIPOSE TISSUE INFLAMMATION AND TUMOR 
MICROENVIRONMENT
Cancer-associated adipocytes
The association between obesity and cancer prognosis has 
been well established, and epidemiological studies support 
a strong correlation between the prevalence of obesity and 
cancer. However, the direct mechanism remains elusive due 
to the complex network of TME compartments (Quail and 
Dannenberg, 2019). Thus, to inspect the impact of adipo-
cytes on proliferating tumors, several studies have conducted 
a co-culture system to observe the direct interplay between 
cancer cells and adipocytes. Though yet to be further estab-
lished, adipokines and cytokines exchanged between two 
compartments dramatically alter the morphology of both cell 
types. Common phenotypes exhibited by the co-culture sys-
tem included adipocytes when grown along with cancer cells 
originating from adipocyte-rich environments, undergoing 
dedifferentiation, and delipidation. Along with the down-
regulation of mature adipocyte markers, these observations 
imply that the cancer-associated adipocytes (CAAs) supply 
the tumorigenic niche to nearby cancer cells followed by adi-
pocyte death (Table 1).
 Notably, CAAs from different tumor origins release im-
portant secretory factors. The chemokine ligand C-X-C mo-
tif chemokine ligand (CXCL) 12 and the receptors, C-X-C 
chemokine receptor (CXCR) 4 and 7, are overexpressed in 
tumors and implicated in cell proliferation, migration, and 
tumor metastasis (Zhou et al., 2019). The binding of CXCL12 
to CXCR4 is now documented to activate divergent signals 
on multiple pathways, such as extracellular signal-regulat-
ed kinase1/2 (ERK1/2), p38, stress-activated protein kinase 
(SAPK)/c-Jun NH(2)-terminal kinase (JNK), Akt, mammalian 
target of rapamycin (mTOR), and Bruton tyrosine kinase. 
CXCL12/CXCR4 flux regulates intracellular calcium flux, che-
motaxis, transcription, and cell survival (Scala, 2015). These 
cytokines are not only secreted by malignant tumors but also 
secreted from adipocytes when co-cultured with certain can-
cers (Laurent et al., 2016).
 Interleukin 6 (IL-6), another major cytokine in the TME, is 
frequently deregulated in cancers. Interestingly, IL-6 secretion 
has been implicated in obese patients and in CAAs co-cul-
tured with breast, ovary, and prostate cancer cells, indicating 
the correlation between IL-6 and AT inflammation (Table 1). 
IL-6 overexpression can promote tumorigenesis and evasion 
of immune surveillance via Janus kinases (JAK) and signal 
transducer and activator of transcription 3 (STAT3) activa-
tion (Fisher et al., 2014; Kang et al., 2019). This mediates 
anti-apoptotic signals such as B-cell lymphoma 2 (Bcl-2), sur-
vivin, and myeloid cell leukemia-1 (Mcl-1), and enhances pro-
liferation by overexpression of c-Myc, Cyclin D1, and MMP 
(Chonov et al., 2019).
Extracellular matrix
ECM remodeling is essential for both AT inflammation and 
tumor growth. Similar to inflammatory AT, the TME ex-
periences modification of ECM stiffness via CAF-mediated 
desmoplasia. Myofibroblasts in TME also deposit stiff matrix 
components, such as fibrillar collagens and fibronectins. As 
previously mentioned, transformation into CAFs is mediated 
via TGF-β, FGF, and PDGF expression from the cancerous 
region, stimulating angiogenesis, cell proliferation, invasion, 
and motility (Karagiannis et al., 2012). These outcomes are 
relatively common in TME with enriched ECM; for example, 
breast cancer becomes abundant with myofibroblasts during 
obesity to promote ECM stiffness (Seo et al., 2015). The tran-
sition of normal fibroblast to CAFs initiates cancer fibrosis by 
increasing the stiffness of the ECM in TME and AT. ECM iso-
lated from inflammatory stromal cells promotes the invasive 
behavior of breast cancer cells by stimulating mechano-signal 
transduction, however, this could be reversed by weight loss 
(Seo et al., 2015). Nintedanib, a tyrosine kinase inhibitor 
targeting platelet-derived growth factor receptor (PDGFR) 
and vascular endothelial growth factor receptor (VEGFR), is a 
well-known chemotherapeutic drug and has been approved 
to treat idiopathic pulmonary fibrosis (IPF) (Rivera-Ortega et 
al., 2018). Similarly, drugs capable of simultaneously alleviat-
ing both inflammatory AT and TME are listed in Table 2.
 Another major regulator of the ECM structure is collagen. 
Collagens are known to be the dominant components of 
ECM in both TME and AT. Specifically, collagen VI deposi-
tion plays a pivotal role in AT to induce epithelial hyperplasia 
(Quail and Dannenberg, 2019). During obesity, collagen VI 
is highly synthesized, which reflects a broad shift toward AT 
fibrosis (Khan et al., 2009). During inflammatory states, AT 
experiences robust changes in ECM, that coincide with the 
delivery of the pro-tumorigenic niche as they disrupt tissue 
homeostasis. Fibrillar collagens that reside in TME directly 
interact with tumor cells to modify the environment, resem-
bling the function of collagens under inflammatory AT.
Angiogenesis
Hypoxic conditions within malignant tumor and inflammato-
ry AT secrete HIF1-α mediated angiogenic factors into their 
adjacent environment. The most prominent factor involved 
in this condition is VEGF. Since oxygen and nutrient demands 
from both proliferating tumor cells and hypertrophic adipo-
cytes are immense, they need to be highly vascularized. How-
ever, the vessel function is often dysfunctional or insufficient 
in both cases. In the case of inflammatory AT, CLS forming 
near the adipocytes are inaccessible to blood vessels. This 
phenomenon is exaggerated in obese patients due to vascu-
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lar control, which is unable to meet the necessary demand 
(Quail and Dannenberg, 2019). Obese patients also demon-
strate higher IL-6 and FGF-2 expression levels, which can 
potentially result in resistance to anti-VEGF therapy. Report-
edly, a mouse model treated with IL-6 blockade abrogated 
resistance to this therapy. Additionally, the downregulation 
of the FGF-2 expression by metformin or FGF receptor inhibi-
tion sensitized obese mice to anti-VEGF therapy (Incio et al., 
2018). Thus, both the inflammatory AT and TME commu-
nicate with nearby elements to facilitate vascularization and 
meet demands.
Macrophages
Complicated networks of TME involve notable players of 
unique classes and subclasses of the tumor immune microen-
vironment (TIME), including tumor-associated macrophages 
(TAMs), myeloid-derived suppressor cells (MDSCs), natural 
killer cells (NKs), dendritic cells (DCs), and T cells (Binnewi-
es et al., 2018). TAMs are responsible to maintain the host 
defense and tissue homeostasis; thus, they are well char-
acterized in both inflammatory TME and AT (Erreni et al., 
2011; Thomas and Apovian, 2017). Correspondingly, TAMs 
are considered major components of tumor-infiltrating im-
mune cells, providing a favorable TME for cancer to develop 
uncontrolled growth, neovascularization, and resistance to 
apoptosis (Chanmee et al., 2014). TAMs are characterized 
by the polarization status, which alternates between M1 and 
M2 polarized macrophages. Frequently expressing M2-like 
phenotypes, TAMs promote tumor progression and contrib-
ute to chemoresistance. Thus, M2 macrophage density often 
correlates with poor prognosis in different types of cancer 
patients. While M1 macrophages counteract cancer progres-
sion and metastasis via pro-inflammatory and antimicrobial 
phenotypes, M2 macrophages facilitate anti-inflammatory re-
sponses, tissue repair and remodeling, and immune tolerance 
(Chanmee et al., 2014). M2 can be further classified into 
M2a, b, c, and d according to their phenotypes, indicating 
the diverse functions of M2 macrophages (Yao et al., 2019). 
M2d macrophages are the most prevalent TAMs to drive 
angiogenesis, immunosuppression, and tumor progression 
(Chanmee et al., 2014). Although the macrophage polar-
ization status is contradictory between inflammatory AT and 
TME, both conditions are associated with high-grade macro-
phage infiltration (Pang et al., 2008). In obese mice, CXCL12 
enhances macrophage recruitment and insulin resistance, 
which could be reversed via CXCL12 blockade (Kim et al., 
2014). In parallel, CXCL12/CXCR4, 7 flux in the TME shapes 
monocyte differentiation to a distinct type of macrophages 
with pro-angiogenic and immunosuppressive phenotypes 
(Sanchez-Martin et al., 2011). MCP-1, the master regulator 
of monocyte/macrophage recruitment, has been implicated 
in multiple adipocyte-rich cancers, such as breast, prostate, 
ovarian, and non-small lung cancers (Table 1). Therefore, 
macrophages, demonstrating alternating behavior of M1 and 
M2 polarization, actively communicate with adjacent com-
partments to support the proliferative niche.
CONCLUSION
The worldwide prevalence of obesity has been dramatically 
increasing for the past decades. Both clinically and exper-
imentally, pathological consequences of AT inflammation 
have been substantially demonstrated. In the presence of 
cancer, obese patients develop chemoresistance with high 
frequency, suggesting that distinct therapeutic approaches 
are required depending on an individual’s metabolic health. 
Body mass index (BMI) and waist circumference are the main 
assessments in assigning obesity; however, this fails to fully 
examine the metabolic health. As AT homeostasis is critical 
for TME, a qualitative analysis, including a systematic his-
tological, biochemical, and gene expression analysis, of AT 
function is necessary when treating cancer.
 Notably, there exist commonalities between growing tu-
mors and dysfunctional AT, indicating that both conditions 
undergo environmental reconstruction to favor growth (Fig. 
1). Interestingly, during simultaneous growth, tumors grow 
more rapidly and invasively (Table 1). Both tumor cells and 
adipocytes secrete cytokines, promote immune cell infiltra-
tions, and reconstruct their microenvironment, supporting 
the transition of tumor behavior to be more malignant. Adi-
pocytes and tumor cells experience hypoxic conditions during 
proliferation, that activates HIF1-α-mediated VEGF, PDGF, 
and FGF expression to further induce angiogenic factors. 
These features of cancer cells and adipocytes reconstruct 
ECM to favor the supply of both inflammatory and tumori-
genic niche.
 An intensive inflammation is a common feature among 
obese cancer patients. Especially those with adipocyte-rich 
cancers experience fatal growth of tumor fueled by chronic 
inflammation within the TME (Quail and Dannenberg, 2019). 
Hence, to counteract the TME which favors rapid progres-
sion, more attempts to reduce secretion of the inflammatory 
cytokines and chemokines should be made by administration 
of non-steroidal anti-inflammatory drugs (NSAIDs). Aspirin, 
for example, plays a critical role in suppressing inflammatory 
environment through inhibition of COX2, making it possi-
ble to be applied in cancer treatment. In addition to aspirin, 
we provide a potential therapeutic approach to target both 
inflammatory AT and TME with a single drug delivery (Table 
2) (Cuzick et al., 2009). For instance, the inhibitory effect of 
metformin on AMPK/mTOR pathway is now implemented 
with numerous chemotherapeutic drugs (Saraei et al., 2019). 
Taking this into account, our rearrangement provides a 
broader application of anti-inflammatory drugs to inhibit the 
secretion of pro-inflammatory agents. Here, we not only sug-
gest both direct and combined applications of anti-inflamma-
tory drugs against tumor progression, but also emphasize the 
necessity to identify the patients’ metabolic health.
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